Ruediger Liersch

TL;DR: In a multivariate analysis that used six cycles of CHOP-14 without rituximab as the reference, and adjusting for known prognostic factors, all three intensified regimens improved 3-year event- free survival and progression-free survival.

TL;DR: It is demonstrated that human keratinocyte-derived skin tumors may evade T cell-mediated antitumor immune responses by down-regulating the expression of CCL27 through the activation of epidermal growth factor receptor (EGFR)–Ras–MAPK-signaling pathways.

TL;DR: Gemcitabine plus oxaliplatin demonstrates antitumor activity with acceptable toxicity in heavily pretreated patients with relapsed or cisplatin-refractory germ cell cancer, and may offer a chance of long-term survival for selected patients.

TL;DR: Findings identify S100A2 as a strong metastasis inducer in vivo and might be a potential biomarker as well as a novel therapeutic target in NSCLC metastasis.

TL;DR: Analysis of expression and relevance of OPN in newly diagnosed AML patients from 2 large study groups provided evidence that OPN expression is an independent prognostic factor in AML.